Treats metastatic renal cell carcinoma. Sold as Proleukin. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Aldesleukin (sold as Proleukin), first approved May 5, 1992, with 2 new uses approved and 0 published complete response letters.
| Phase I Trial of Subcutaneous VDJ010 In Healthy Subjects and Patients With Ulcerative ColitisUlcerative Colitis (UC) · Beijing VDJBio Co., LTD. | Phase 1 | Recruiting | Nov 12, 2026 |
| Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney CancerKidney Cancers, Renal Cell Carcinoma (Kidney Cancer) · Beth Israel Deaconess Medical Center | Phase 2 | Not yet recruiting | Nov 9, 2026 |
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue SarcomaSarcoma, Soft Tissue Sarcoma (STS) · Iovance Biotherapeutics, Inc. | Phase 2 | Recruiting | Aug 3, 2026 |
| A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple Myeloma · AstraZeneca | Phase 1 / Phase 2 | Recruiting | Jul 2, 2026 |
| A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic MelanomaMelanoma (Skin Cancer), Melanoma Metastatic · East Metropolitan Health Service, Australia | Phase 2 | Not yet recruiting | Jun 16, 2026 |
| Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's DiseaseAlzheimer Dementia (AD) · The Methodist Hospital Research Institute | Phase 1 / Phase 2 | Recruiting | Jun 16, 2026 |
| Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal TumorsLocally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor · Joal Beane | Phase 2 | Not yet recruiting | Jun 15, 2026 |
| Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T CellsCoronary Artery Disease, Myocardial Infarction (MI) · Cambridge University Hospitals NHS Foundation Trust | Not applicable | Recruiting | May 28, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA